Capecitabine combined with irinotecan (XELIRI) is not recommended in major cancer guidelines due to toxicity. The recent experimental results show that mXELIRI regimen (improved xeiriri regimen) has good efficacy and safety in the treatment of metastatic colorectal cancer. MXELIRI regimen: irinotecan 200mg/m2, day 1 day; Capecitabine 1600mg/m2, from day 1 day to day 14, every three weeks 1 cycle, with or without bevacizumab (7.5mg/kg, day 1 day).
From February 20 13 to August 20 15, AXEPT trial included 650 patients with mCRC confirmed by histology. They were randomly divided into standard FOLFIRI bevacizumab treatment group (n=324) and mXELIRI bevacizumab treatment group (n=326) according to the ratio of 1: 1. The median follow-up time was 65438 05.8 months.
The results showed that the median overall survival time was 65438 06.8 months in mXELIRI group and 65438 05.4 months in FOLFIRI group, P < 0.00065438±0.05.
The incidence of grade 3 /4 adverse events in mXELIRI group was significantly lower than that in FOLFIRI group, which were 53.9% and 72.3% respectively, P < 0.005438+0.0 1. The common grade 3 /4 adverse event was central neutropenia, which was 65438 06.8% in mXELIRI group and 42.9% in FOLFIRI group, P < 0.0005438±0.05.
refer to
T.Kim, Y. Park, K. Muro, et al., Randomized, noninferiority and phase III trial of second-line chemotherapy (mCRC) for metastatic colorectal cancer, to compare the efficacy and safety of XELIRI+bevacizumab and FOLFIRI+bevacizumab (AXEPT).